Naturecell Co., Ltd. (007390) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Naturecell Co., Ltd. (007390:KRX), powered by AI.

Current Price
₩32,200
P/E Ratio
-731.0
Market Cap
2.1T
Sector
Common Stock
What is the Naturecell Co., Ltd. stock price forecast?

Naturecell Co., Ltd. is currently trading at ₩32,200. View real-time AI analysis on Alpha Lenz.

What is Naturecell Co., Ltd. insider trading activity?

View the latest insider trading data for Naturecell Co., Ltd. on Alpha Lenz.

What is Naturecell Co., Ltd.'s P/E ratio?

Naturecell Co., Ltd.'s P/E ratio is -731.0.

Naturecell Co., Ltd.

KRX · 007390
₩32,200+1,650(+5.40%)Market closedKRX regular session 09:00–15:30 KST
Ask about Naturecell Co., Ltd.'s future dividend policy...
Alpha Chat Insight

Naturecell Co., Ltd. trades at a P/E of -731.0 (undervalued) with modest ROE of -4.4%.

Ask for details

Company Overview

Naturecell Co., Ltd. is a biotechnology company primarily focused on the development, production, and commercialization of cell therapy products. The company operates in the burgeoning biopharmaceutical industry, aiming to leverage stem cell technologies to offer innovative treatment options for a range of medical conditions. It engages in research and development efforts to create therapies that can enhance regenerative processes in the human body, particularly targeting diseases that currently have limited treatment avenues. Naturecell Co., Ltd. is dedicated to advancing therapeutic solutions that can address unmet medical needs, potentially impacting healthcare outcomes significantly. The company’s presence in the market underscores the growing importance of biotechnology and regenerative medicine in modern healthcare. By investing in cutting-edge research and employing advanced biotechnologies, Naturecell Co., Ltd. plays a critical role in the evolution of medical treatments, positioning itself as a key player in the sector. With its focus on innovation and the application of cell therapy, the firm contributes to the broader objective of developing sustainable and effective healthcare solutions worldwide.

CEO변대중
SectorCommon Stock
IndustryCommon Stock
0

Company Statistics

FY 2025

Profile

₩2,074,808,803,200Market Cap
₩20,734,613,570Revenue
64.44MShares Out
0Employees

Margins

45.61%Gross
-2.74%EBITDA
-17.46%Operating
-13.34%Pre-Tax
-13.69%Net

Valuation

-731.00P/E
32.92P/B
100.06EV/Sales
-3638.34EV/EBITDA
-126.25P/FCF

Growth (CAGR)

-0.82%Rev 3Yr
4.40%Rev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-3.87%ROA
-4.45%ROE
-3.50%ROIC

Financial Health

₩16,767,416,000Cash & Cash Equivalents
₩-5,065,827,900Net Debt
18.57%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Naturecell Co., Ltd. (ticker: 007390) is a company listed on KRX in the Common Stock sector (Common Stock). Market cap is $2.1T.

The current price is ₩32,200 with a P/E ratio of -731x and P/B of 32.92x.

ROE is -4.45% and operating margin is -17.46%. Annual revenue is $20.7B.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Naturecell Co., Ltd. (007390) Stock Forecast 2026 ₩32,200 — Price, Financials & Analyst Targets | Alpha Lenz